NCT06720207Not yet recruiting
Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions
Exploratory Study on the Efficacy of 68Ga-Pentixafor PET/MR in Detecting Lesions in Non-Hodgkin Lymphoma and Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 27 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 27 Nov 2024
- Start date
- 1 Jul 2025
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Shanghai East Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT06720207
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 Jul 2025 to the primary completion date, 31 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with concurrent malignancies;
- Patients containing metallic implants;
Other illness
- Individuals with severe hepatic and renal failure;
Other
- Pregnant and breastfeeding women;
- Individuals unable to remain supine for a duration of 30 minutes to complete the examination;
- Patients with diagnosed claustrophobia;
- Individuals deemed unsuitable for participation in clinical trials by researchers.
Who the study is looking for
- Age of 18 years or older
- ECOG \< 2
- Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination
- Completion of 18F-FDG PET/CT or PET/MR imaging within the past week in our department
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.